The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The Company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. Active clinical pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis). The members of the Processa development team have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers.
Applying FDA’s Project Optimus to the Development of Next Generation Chemotherapy Treatment of Rare Cancers – WODC May 24, 2023View This Presentation
Pharmaceutical Preparation Manufacturing (325412)
Pharmaceutical Preparations (2834)
Processa Pharmaceuticals, Inc.
7380 Coca Cola Drive
Hanover, MD 21076